Enasidenib is an inhibitor of IDH2. It is a drug used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene. The drug was discovered in 2009 by scientists at Agoios and the development names for the drug was AG-221 and CC-90007.

Enasidenib was approved by the FDA in August 2017. The trade name under which it was approved was Idhifa.

6-[6-(Trifluoromethyl)-2-pyridinyl]-1,3,5-triazine-2,4(1H,3H)-dione is one of KMS of Enasidenib, the appearance is white to off-white powder solid, the purity is not less than 99% by HPLC.